Several novel compounds are under investigation aimed to enhance the antitumor immune-activity through T-cell and NK-cell modulation, such as new checkpoint inhibitors, the CD16xCD30—NK-engaging bispecific antibody AFM13 and the anti-CD25 ADC Cami-T, revealing promising efficacy in the R/R cHL setting. The gene discussed is IL2RA; the disease is classic Hodgkin lymphoma.